These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 21309780)
21. [Desensitization to mites: literature review]. Castel M; Leroy-Maguer C Allerg Immunol (Paris); 1994 Jan; 26(1):31-7. PubMed ID: 8166939 [TBL] [Abstract][Full Text] [Related]
22. Design and endpoints of clinical trials in hepatocellular carcinoma. Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ; J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802 [TBL] [Abstract][Full Text] [Related]
23. [Research methodology: A guarantee for progress in knowledge about infections]. Carballo Alvarez F Rev Esp Quimioter; 2001 Jun; 14(2):126-37. PubMed ID: 11704767 [No Abstract] [Full Text] [Related]
24. Statistical management of data in clinical research. Fleiss JL; Kingman A Crit Rev Oral Biol Med; 1990; 1(1):55-66. PubMed ID: 2101261 [No Abstract] [Full Text] [Related]
25. TIPSS trials: design determines outcome. Jalan R; Finlayson ND; Hayes PC Hepatology; 1997 Nov; 26(5):1361-5. PubMed ID: 9362385 [No Abstract] [Full Text] [Related]
26. The value of information and optimal clinical trial design. Willan AR; Pinto EM Stat Med; 2005 Jun; 24(12):1791-806. PubMed ID: 15806619 [TBL] [Abstract][Full Text] [Related]
27. [Methodological and statistical aspects of equivalence and non inferiority trials]. Elie C; De Rycke Y; Jais JP; Marion-Gallois R; Landais P Rev Epidemiol Sante Publique; 2008 Aug; 56(4):267-77. PubMed ID: 18703296 [TBL] [Abstract][Full Text] [Related]
28. Outcomes for disease modifying trials. Wilcok G J Nutr Health Aging; 2007; 11(4):318-9. PubMed ID: 17653489 [No Abstract] [Full Text] [Related]
29. Bayesian design and analysis of two x two factorial clinical trials. Simon R; Freedman LS Biometrics; 1997 Jun; 53(2):456-64. PubMed ID: 9192445 [TBL] [Abstract][Full Text] [Related]
35. A primer on the design, conduct, and interpretation of clinical trials. Appel LJ Clin J Am Soc Nephrol; 2006 Nov; 1(6):1360-7. PubMed ID: 17699370 [TBL] [Abstract][Full Text] [Related]
37. Response adaptive designs with a variance-penalized criterion. Yi Y; Wang X Biom J; 2009 Oct; 51(5):763-73. PubMed ID: 19757432 [TBL] [Abstract][Full Text] [Related]
38. Reducing risk and improving efficacy of clinical trials: the adaptive design. Dangi-Garimella S Am J Manag Care; 2014 Aug; 20(11 Spec No.):E8. PubMed ID: 25618150 [No Abstract] [Full Text] [Related]
39. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. Tang PA; Bentzen SM; Chen EX; Siu LL J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010 [TBL] [Abstract][Full Text] [Related]
40. Platelet microRNA profiles and the effect of pathogen reduction on platelet function. Hitzler W; Vamvakas EC Clin Lab; 2011; 57(7-8):451-4. PubMed ID: 21888008 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]